Valeant And Pershing May Sweeten Allergan Deal By $15 A Share

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Bill Ackman’s Pershing Square are said to be planning to boost their offer to acquire Botox maker Allergan, Inc. (NYSE:AGN) by $15 a share, according to people familiar with the developments. The enhanced offer marks Valeant and Pershing Square’s third increase to their original bid. Valeant – Allergan merger could be the largest deal of the year The latest bid from Valeant Pharmaceuticals and Pershing is intended to keep the Botox maker from striking a rival deal. The duo’s bid could value Allergan at over $56 billion, increasing the earlier offer by $4.5 billion. If…